Activated PI3Kδ syndrome 患者末梢血B細胞におけるAKTの過剰リン酸化 by Asano, Takaki
April 2018 | Volume 9 | Article 5681
Original research
published: 05 April 2018
doi: 10.3389/fimmu.2018.00568
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Stuart G. Tangye, 
Garvan Institute of Medical 
Research, Australia
Reviewed by: 
Michel Massaad, 
American University of 
Beirut Medical Center, Lebanon 
Silvia Clara Giliani, 
University of Brescia, Italy  
Vanessa L. Bryant, 
Walter and Eliza Hall Institute of 
Medical Research, Australia
*Correspondence:
Satoshi Okada  
saok969@gmail.com
Specialty section: 
This article was submitted 
to Primary Immunodeficiencies, 
a section of the journal 
Frontiers in Immunology
Received: 30 November 2017
Accepted: 06 March 2018
Published: 05 April 2018
Citation: 
Asano T, Okada S, Tsumura M, 
Yeh T-W, Mitsui-Sekinaka K, Tsujita Y, 
Ichinose Y, Shimada A, Hashimoto K, 
Wada T, Imai K, Ohara O, Morio T, 
Nonoyama S and Kobayashi M 
(2018) Enhanced AKT 
Phosphorylation of Circulating 
B Cells in Patients With Activated 
PI3Kδ Syndrome. 
Front. Immunol. 9:568. 
doi: 10.3389/fimmu.2018.00568
enhanced aKT Phosphorylation  
of circulating B cells in Patients  
With activated Pi3K  syndromeδ
Takaki Asano1, Satoshi Okada1*, Miyuki Tsumura1, Tzu-Wen Yeh2,  
Kanako Mitsui-Sekinaka3, Yuki Tsujita3, Youjiro Ichinose4, Akira Shimada5,  
Kunio Hashimoto6, Taizo Wada7, Kohsuke Imai8, Osamu Ohara9, Tomohiro Morio2,  
Shigeaki Nonoyama3 and Masao Kobayashi1
1 Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, 
2 Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 
3 Department of Pediatrics, National Defense Medical College, Tokorozawa, Japan, 4 Department of Pediatrics,  
Ako Central Hospital, Ako, Japan, 5 Department of Pediatrics, Okayama University Graduate School of Medicine, Okayama, 
Japan, 6 Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 
7 Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 
Kanazawa, Japan, 8 Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental 
University (TMDU), Tokyo, Japan, 9 Department of Technology Development, Kazusa DNA Research Institute, Kisarazu, Japan
Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency characterized by 
recurrent respiratory tract infections, lymphoproliferation, and defective IgG production. 
Heterozygous mutations in PIK3CD, PIK3R1, or PTEN, which are related to the hyper-
active phosphoinositide 3-kinase (PI3K) signaling, were recently presented to cause 
APDS1 or APDS2 (APDSs), or APDS-like (APDS-L) disorder. In this study, we examined 
the AKT phosphorylation of peripheral blood lymphocytes and monocytes in patients 
with APDSs and APDS-L by using flow cytometry. CD19+ B cells of peripheral blood 
in APDS2 patients showed the enhanced phosphorylation of AKT at Ser473 (pAKT) 
without any specific stimulation. The enhanced pAKT in CD19+ B cells was normalized 
by the addition of a p110δ inhibitor. In contrast, CD3+ T cells and CD14+ monocytes did 
not show the enhanced pAKT in the absence of stimulation. These findings were similarly 
observed in patients with APDS1 and APDS-L. Among CD19+ B cells, enhanced pAKT 
was prominently detected in CD10+ immature B  cells compared with CD10− mature 
B cells. Enhanced pAKT was not observed in B cells of healthy controls, patients with 
common variable immunodeficiency, and hyper IgM syndrome due to CD40L deficiency. 
These results suggest that the enhanced pAKT in circulating B cells may be useful for the 
discrimination of APDS1, APDS2, and APDS-L from other antibody deficiencies.
Keywords: activated Pi3 kinase delta syndrome, aKT phosphorylation, catalytic subunit p110δ of 
phosphatidylinositol 3-kinase, flow cytometry, immunodeficiency, regulatory subunit p85α of phosphatidylinositol 
3-kinase
Abbreviations: APDS, activated PI3Kδ syndrome; APDS1, activated PI3Kδ syndrome 1; APDS2, activated PI3Kδ syndrome 2; 
APDS-L, activated PI3Kδ syndrome like immunodeficiency; APDSs, activated PI3Kδ syndrome 1 and activated PI3Kδ syndrome 
2; AUC, area under the curve; cDNA, complementary DNA; CI, confidence interval; CMV, cytomegalovirus; CVID, common 
variable immunodeficiency; ΔMFI, difference in mean fluorescence intensity; EZR, Easy R; EBV, Epstein Barr virus; GOF, gain 
of function; HIGM, hyper IgM syndrome; IVIG, intravenous immunoglobulin; LOF, loss of function; MFI, mean fluorescence 
intensity; mTOR, mechanistic target of rapamycin; NK, natural killer; PBMCs, peripheral blood mononuclear cells; PCR, poly-
merase chain reaction; PI3K, phosphoinositide 3-kinase; PID, primary immunodeficiency syndrome; PIP2, phosphatidylinositol 
3, 4- triphosphate; PIP3, phosphatidylinositol 3, 4, 5- triphosphate; PHTS, PTEN Hamartoma Tumor Syndromes; PTEN, phos-
phatase and tensin homolog; ROC, receiver operating characteristic; Ser473, Serine473; pAKT, AKT phosphorylation.
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inTrODUcTiOn
Activated PI3Kδ syndrome (APDS) is a primary immunodefi-
ciency (PID) characterized by recurrent respiratory tract infec-
tions, chronic Epstein Barr virus and cytomegalovirus infections, 
lymphoproliferation, increased lymphoma susceptibility, and 
poor antibody production (1–4). Heterozygous gain-of-function 
mutations in PIK3CD, which encodes the catalytic subunit p110δ 
of phosphoinositide 3-kinase (PI3K), have been identified in 
patients with APDS1 (1, 3). Subsequent studies have demon-
strated that a heterozygous mutation in PIK3R1 encoding p85α, 
a regulatory subunit of PI3K, is responsible for APDS2: a PID 
with similar clinical manifestations to APDS1 (2, 4). Moreover, a 
patient with a heterozygous loss-of-function mutation in PTEN, 
which encodes phosphatase and tensin homolog and is associated 
with PTEN hamartoma tumor syndrome (PHTS), was recently 
reported to develop APDS-like immunodeficiency (APDS-L) 
with incomplete penetrance (5, 6).
Phosphoinositide 3-kinases convert phosphatidylinositol 
3,4-triphosphate (PIP2) to phosphatidylinositol 3,4,5-triphos-
phate (PIP3) and are involved in cellular functions including 
proliferation, differentiation, survival, and trafficking (7, 8). Both 
p110δ and p85α belong to class IA PI3Ks and have an essential 
role in the differentiation, development, and functions of several 
distinct stages of B- and T-lymphocytes (7, 8). They also have an 
important role in the antibody maturation process by regulating 
immunoglobulin class-switch recombination and plasma cell 
differentiation (9). When stimulated, PIP3 recruits AKT to the 
plasma membrane where AKT is activated via phosphorylation 
by PDK1 and mTORC2 (7, 8). In contrast, PTEN antagonizes 
PI3Ks by catalytic dephosphorylation of PIP3 to PIP2 (10). The 
recent identification of APDS1 and APDS2 (APDSs) and APDS-L 
revealed that the hyperactive PI3K/AKT signaling affects the 
immune system in humans, leading to the development of PID.
Here, we investigated four unrelated Japanese patients with 
APDS2 caused by a heterozygous mutation in PIK3R1. Activated 
T cells from the patients showed enhanced phosphorylation of 
Ser473 of AKT (pAKT) consistent with findings in previous 
reports (2, 4). We next investigated the status of pAKT using 
peripheral blood mononuclear cells (PBMCs) isolated from 
patients and analyzed by flow cytometry. We observed that 
circulating CD19+ B cells from APDS2 patients, but not other 
cell populations, showed enhanced pAKT. This finding was 
similarly detected in circulating CD19+ B  cells from patients 
with APDSs or APDS-L, but not from healthy controls, com-
mon variable immunodeficiency (CVID) patients, or hyper 
IgM syndrome (HIGM) patients due to CD40L deficiency. 
Therefore, enhanced pAKT signaling in circulating CD19+ 
B cells was considered a specific finding in patients with APDSs 
or APDS-L. Furthermore, by focusing on CD10+CD19+ imma-
ture B cells, this method allowed us to distinguish APDSs and 
APDS-L patients from healthy controls and patients with CVID 
or HIGM (CVID/HIGM). This flow-cytometry-based assay of 
PI3K activity enabled the discrimination analysis of identified 
mutations in PIK3CD, PIK3R1, or PTEN. It may also serve as a 
rapid diagnostic method to discriminate APDSs and APDS-L 
patients from other PID.
MaTerials anD MeThODs
cases
We investigated four unrelated Japanese patients with APDS2 
who were involved in a previous international survey (P13, 
P14, P19, and P26 in the previous report) (11). The detailed 
clinical manifestations of those patients are available in 
Materials and Methods in Supplementary Material. All of the 
patients carried heterozygous germline mutations in PIK3R1 
(Figure S1 in Supplementary Material). The identification 
of PIK3R1 mutation was performed by a candidate gene 
approach in P4. For the other three patients, the mutations 
were identified by whole exome sequencing and were con-
firmed by Sanger sequencing. The identified mutations were 
1425 + 2 T > A (P1), 1300−1 G > C (P2), 1425 + 1 G > C (P3), 
and 1425 + 1 G > T (P4). The PIK3R1 mutations identified in 
P3 and P4 were previously shown to be pathogenic mutations 
(2, 4).
We included four CVID patients, aged 33 (P5), 36 (P6), 17 
(P7), and 30 (P8) years, whose genetic causes have not been 
identified (detailed in Materials and Methods in Supplementary 
Material). The absence of pathogenic mutations in PIK3CD, 
PIK3R1, and PTEN was confirmed in those patients. We also 
included one HIGM patient due to CD40L deficiency (P9) 
who was 41  years old (detailed in Materials and Methods in 
Supplementary Material).
immunoblot analysis
CD3+ T cells and CD19+ B cells were separated from PBMCs 
using the IMag™ Cell Separation System (BD Biosciences, 
San Jose, CA, USA). The separated cells were then subjected 
to immunoblot analysis using the following antibodies: anti-
AKT antibody (Cell Signaling Technology, Danvers, MA, 
USA), anti-phospho-AKT (Ser473) antibody (Cell Signaling 
Technology), and ß-actin (SIGMA-ALDRICH, Saint Louis, 
MO, USA).
Preparation of activated T cells
Activated T cells were derived from PBMCs according to a previ-
ous report (2). Briefly, PBMCs were cultured with 1 × 106 cells 
per mL in RPMI 1640 GlutaMax supplemented with 10% human 
AB serum, penicillin and streptomycin, PMA (1  µmol/L), and 
ionomycin (20 ng/mL) for 2 days. The cells were then separated 
by Lymphoprep density-gradient centrifugation and washed 
twice with RPMI 1640 GlutaMax. Then, they were cultured in 
RPMI 1640 GlutaMax supplemented with 10% human AB serum 
and IL-2 (100 IU/mL) for 16–24 h.
B-cell stimulation
For B-cell stimulation, PBMCs were purified by Lymphoprep 
density-gradient centrifugation and incubated at 1 × 106 cells per 
mL in RPMI 1640 GlutaMax supplemented with 10% human AB 
serum, penicillin, and streptomycin. The cells were stimulated 
with CD40L (1 µg/mL) and IL-4 (20 ng/mL) for 30 min. They 
were then harvested and subjected to flow-cytometry analysis of 
AKT phosphorylation.
FigUre 1 | The effect of splice site mutation identified in P1. (a) A germline heterozygous mutation, (B) 1425 + 2 T > A, in PIK3R1 was identified by whole exome 
sequencing and confirmed by Sanger sequencing. (c) mRNA was extracted from peripheral blood mononuclear cells from P1 and his mother. Complementary DNA 
was then synthesized to assess the significance of the nucleotide substitution, 1425 + 2 T > A, on splicing. (c,D) The RT-PCR fragment was cloned into a pGEM-T 
easy vector. Loss of exon 10 in patient (c) but not mother (D) was revealed by Sanger sequencing.
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Flow-cytometry analysis of aKT 
Phosphorylation
Peripheral blood mononuclear cells from APDS1 (four patients), 
APDS2 (four patients), APDS-L (four patients), CVID (four 
patients), HIGM (one patient), and 24 adult healthy controls 
were subjected to flow-cytometry analysis. We assessed pAKT 
at Ser473 by flow cytometry as follows. PBMCs were suspended 
at a density of 1 ×  106  cells/μL in serum-free RPMI with or 
without 10 µM of 110δ inhibitor (IC87114) in the presence of 
FITC-conjugated anti-CD19 (HIB19) (BD Biosciences). The 
cells were incubated for 20 min at 37°C and washed twice. They 
were fixed and permeabilized according to the BD Phosflow 
protocol (protocol III). They were then stained and subjected 
to flow cytometry. The following antibodies were used for stain-
ing: Alexa Fluor 647-conjugated anti-phospho AKT (Ser473) 
(D9E) (Cell Signaling Technology), FITC-conjugated anti-
CD19 (BD Biosciences), PE-conjugated anti-CD3 (UCHT1) 
(BD Biosciences), PE-conjugated anti-CD14 (Mφ97) (BD 
Biosciences), or FITC-conjugated anti-CD56 (C5.9) (SIGMA-
ALDRICH), PE-conjugated CD16 (3G8) (BD Biosciences), and 
PerCP-Cy 5.5-conjugated anti-CD10 (HI10a) (BD Biosciences). 
Negative selection of B cells from PBMCs was performed using 
Pan B-Cell Isolation Kit, human (Miltenyi Biotec Inc., Auburn, 
CA, USA).
statistical analysis
Receiver operating characteristic (ROC) curves were created with 
Easy R (EZR) software available online (http://www.jichi.ac.jp/
saitama-sct/SaitamaHP.files/statmedEN.html). EZR is statistical 
software and is based on R and R commander. EZR enables the 
application of statistical functions (12). Statistical hypotheses 
were tested using a two-tailed t-test. A p value < 0.05 was con-
sidered significant.
resUlTs
Mutation analysis of Patients With aPDs2
We found a splice site mutation at the +  2 position following 
exon 10 (Figure 1A). Amplification of cDNA showed an aber-
rant, faster migrating band suggesting a deletion (Figure  1B). 
Sanger sequencing demonstrated a deletion of exon 10 in the 
patient (Figure  1C) but not in his mother (Figure  1D). Thus, 
we confirmed that the identified PIK3R1 mutations in P1, as 
well as the other two mutations, are pathogenic mutations, 
leading to the skipping of exon 10 with a deletion of amino acid 
residues 434–475 of p85α (Figure 1B). The former diagnosis of 
four patients with APDS2 was CVID (P1), HIGM (P2 and P4), 
and IgG subclass deficiency (P3). The identified mutations in 
PIK3R1 were de novo in Family B, C, and D, since we found no 
FigUre 2 | Flow-cytometry-based AKT phosphorylation (pAKT) assay of PMBCs. (a) The level of pAKT in the presence or absence of p110δ inhibitor treatment 
was assessed by flow cytometry in total peripheral blood mononuclear cells (PBMCs), CD3+ T cells, CD14+ monocytes, and CD16+CD56+ natural killer cells from 
activated PI3Kδ syndrome 2 (APDS2) (P1), common variable immunodeficiency (CVID) (P8), or hyper IgM syndrome (HIGM) (P9). The number of events analyzed 
was >5,000. Red bold line: no treatment and black dotted line: p110δ inhibitor treatment. (B) The level of pAKT in negatively selected B cells from PBMCs from P1 
and one healthy control was compared with pAKT in CD19+ B cells. Red solid line: no treatment and black dotted line: p110δ inhibitor treatment. (c) A summary of 
difference in mean fluorescence intensity of whole lymphocytes derived from 24 adult healthy controls or all of the patients with APDS2 or CVID/HIGM. There is no 
statistical significant among this three groups (control vs. CVID; p = 0.24, APDS2 vs. CVID; p = 0.13, and control vs. APDS2; p = 0.52).
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asymptomatic carrier in a familial study. In order to determine 
the mechanism of disease in patients with APDS2, we focused on 
pAKT function associated with PI3K signaling.
circulating cD19+ B cells From Patients 
With aPDss or aPDs-l showing 
enhanced paKT signaling
Enhanced pAKT signaling associated with hyperactive PI3K 
signaling is a common finding in patients with APDSs (1–4). We 
first assessed the status of pAKT in fresh (non-cultured) PBMCs 
from APDS2 patients by flow cytometry. There was no obvious 
difference in the level of pAKT in CD3+ T cells, CD16+CD56+ 
natural killer (NK) cells, and CD14+ monocytes between APDS2 
patients and healthy controls (Figure  2A). In P1’s CD14+ 
monocytes, pAKT was slightly enhanced in the absence of p110δ 
inhibitor treatment compared with untreated, but this difference 
was non-significant. In contrast, CD19+ B cells from the APDS2 
patient (P1) had significantly higher levels of pAKT compared 
with those from healthy controls. By treating them with a p110δ 
inhibitor, the enhancement of pAKT observed in CD19+ B cells 
was normalized. In order to exclude the possibility of stimula-
tion of B  cells by staining them with anti-CD19 antibody, we 
confirmed this finding by analyzing circulating B cells separated 
by negative selection (Figure 2B).
We measured the mean fluorescence intensity (MFI) of pAKT 
in the presence or absence of p110δ inhibitor treatment by flow 
cytometry. We then evaluated enhanced pAKT signaling by 
FigUre 3 | Enhanced AKT phosphorylation (pAKT) in CD19+ B cells from patients with activated PI3Kδ syndromes (APDSs) or APDS-like (APDS-L). (a) Total AKT 
expression in CD19+ B cells from APDS2 patients (P1) was measured by flow-cytometry. Red bold line: activated PI3Kδ syndrome 2 (APDS2) patient and black 
dotted line: healthy control. (B) The phosphorylation and protein expression of AKT was investigated by immunoblotting. (c) pAKT (pS473) in the presence of p110δ 
inhibitor was analyzed by flow cytometry in CD19+ B cells from healthy controls and patients with APDS1, APDS2, or APDS-L, CVID/HIGM. The number of events 
analyzed was >5,000. (D) A summary of difference in mean fluorescence intensity of CD19+ B cells derived from healthy controls or patients with APDS1  
(four patients), APDS2 (P1, P2, P3, and P4), APDS-L (four patients), or CVID/HIGM (P5, P6, P7, P8, and P9). *p < 0.05 and **p < 0.01.
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calculating the difference in MFI (ΔMFI) of pAKT in CD19+ 
B  cells as the difference between MFI (the absence of p110δ 
inhibitor) and MFI (the presence of p110δ inhibitor). CD19+ 
B  cells from APDS2 patients had significantly higher ΔMFI of 
pAKT than those from healthy controls or CVID/HIGM patients, 
although ΔMFI of pAKT in whole lymphocytes was almost at 
the same levels among all individuals (Figures  2C and 3D). 
The protein expression of total AKT in CD19+ B cells from an 
APDS2 patient (P1) was equivalent to that in healthy controls 
(Figure 3A). The result was consistent with the previous stud-
ies showing the normal AKT protein expression in APDSs and 
APDS-L patients (1–4, 6). The enhancement of pAKT in CD19+ 
B cells was confirmed by immunoblotting (Figure 3B; Figure S2 
in Supplementary Material). In contrast, there was no difference 
in the level of pAKT in CD3+ T cells (Figure 3B; Figure S2 in 
Supplementary Material).
We next tested the hypothesis that enhanced pAKT signaling 
in CD19+ B cells is a common finding of patients with hyperactive 
PI3K signaling. We analyzed PBMCs from patients with APDS1 
or APDS-L carrying a heterozygous mutation in PIK3CD or 
PTEN, respectively. As expected, CD19+ B cells from APDS1 and 
APDS-L showed significantly higher levels of pAKT compared 
with healthy controls and CVID/HIGM patients (Figure  3C). 
As above, the enhancement of pAKT observed in these patients 
was normalized by treatment with a p110δ inhibitor. Similar 
to the results obtained from patients with APDS2, the level of 
pAKT was normal in CD3+ T cells, CD16+CD56+ NK cells, and 
CD14+ monocytes from patients with APDS1 or APDS-L (data 
not shown). However, CD19+ B cells and other cell populations 
from patients with CVID and HIGM had normal levels of pAKT 
expression (Figure 2A). Curiously, CD19+ B cells from APDS2 
patients had the highest ΔMFI of pAKT among all APDSs patients 
6Asano et al. pAKT in APDS
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(Figure  3D), followed by elevated ΔMFI of pAKT in APDS-L 
patients observed as significantly higher than healthy controls 
and CVID/HIGM patients (Figure 3D). In addition, higher levels 
of pAKT were also observed in CD19+ B cells from cryopreserved 
PBMCs (Figures S3A,B in Supplementary Material). Therefore, 
the enhancement of pAKT in CD19+ B cells was considered to 
be a specific finding among patients with APDSs and APDS-L.
enhanced paKT signaling in activated  
T cells From aPDs2 Patients
The previous study showed the enhancement of pAKT signal-
ing in activated T cells from APDSs (1–4). We next investigated 
pAKT levels in activated T  cells derived from PBMCs by flow 
cytometry. CD3+CD4+ and CD3+CD8+-activated T  cells from 
P1 showed enhanced pAKT compared with those from healthy 
controls (Figure 4A). The enhancement of pAKT observed in P1 
was normalized by treating cells with a p110δ inhibitor. The result 
was consistent with previous studies that investigated activated 
T cells from patients with APDSs (1–4). Thus, we confirmed the 
enhancement of pAKT in activated T cells from APDS2 patients 
by flow cytometry. Next, we stimulated B cells with CD40L and 
IL-4 and investigated the level of pAKT. Following stimulation 
with CD40L and IL-4, we observed the enhancement of pAKT 
in CD19+ B  cells from APDS2 patient and healthy control 
(Figure 4B). However, this difference became less striking after 
CD40L and IL-4 stimulation.
The enhancement of paKT in Patients 
With aPDss Pronounced in cD10+cD19+ 
immature B cells
Phosphoinositide 3-kinase signaling has important roles in dif-
ferentiation, development, and functions in several distinct stages 
of B and T cells (7, 8). Patients with APDS1, APDS2, or APDS-L 
had increased numbers of transitional B cells in the peripheral 
blood, possibly reflecting the pivotal role of PI3K signaling in 
the differentiation of B cells (1–5). In our study, APDS2 patients 
had increased numbers of transitional B cells in peripheral blood 
consistent with previous studies (Figure S4 in Supplementary 
Material). We investigated pAKT levels in CD19+ B  cells by 
dividing them into three developmental stages: (i) total CD19+ 
B cells, (ii) CD10−CD19+ mature B cells, and (iii) CD10+CD19+ 
immature B cells (corresponding to transitional B cells) by flow 
cytometry (Figure S5 in Supplementary Material). CD19+ B cells 
at all three developmental stages from patients with APDS1, 
APDS2, or APDS-L had higher levels of pAKT compared with 
healthy controls. Surprisingly, the enhancement of pAKT was 
most pronounced in CD10+CD19+ immature B-cell populations 
from APDS1, APDS2, or APDS-L patients (Figure 5). This finding 
was confirmed by CD10+ negatively selected B cells, controlling 
for the potential B-cell activation by anti-CD19 antibody staining 
(Figure S6 in Supplementary Material).
establishment of a Flow-cytometry-Based 
rapid Discrimination assay Based on the 
enhancement of Pi3K signaling
We found that CD19+ B cells from APDSs or APDS-L patients 
had significantly higher levels of pAKT than healthy controls 
and patients with CVID or HIGM. The higher level of pAKT 
observed in these patients was normalized by treating the cells 
with a p110δ inhibitor. This discovery led us to the idea that the 
detection of enhanced pAKT signaling in CD19+ B cells is a useful 
diagnostic tool for the rapid discrimination study of suspected 
APDS patients. CD19+ B cells from patients with APDS2 had the 
highest ΔMFI of pAKT among all APDSs or APDS-L patients. In 
contrast, elevated ΔMFI of pAKT in CD19+ B cells was modest 
in APDS-L patients (Figure 3D). We next analyzed the ΔMFI of 
pAKT in CD10−CD19+ and CD10+CD19+ B cells. As expected, 
the ΔMFI of pAKT was high in both B-cell populations from 
APDSs or APDS-L patients when compared with those from 
healthy controls (Figures 5C–E). The high ΔMFI of pAKT was 
emphasized in the analysis of CD10+CD19+ immature B  cells 
(Figure  5E). Moreover, if we focused on CD10+CD19+ imma-
ture B cells, there was no overlap in the value of ΔMFI between 
APDSs and APDS-L patients and the other populations including 
healthy controls and CVID/HIGM patients. This finding strongly 
suggests that the flow-cytometry-based assay to measure the 
ΔMFI of pAKT can be used as a discrimination assay to detect 
the enhancement of PI3K activity in patients with APDSs and 
APDS-L (flow chart is shown in Figure S7 in Supplementary 
Material).
cutoff Value of ΔMFi of paKT segregating 
aPDss and aPDs-l Patients
We created an ROC curve based on the results of the ΔMFI of 
pAKT obtained from the analysis of CD19+ B  cells. We used 
EZR for statistical analysis and set up the cutoff value of ΔMFI 
of pAKT as 117. This cutoff value allows the segregation of 
APDSs and APDS-L patients from healthy controls or CVID 
patients with 100% sensitivity and 96.0% specificity (Figure S8 
in Supplementary Material). The area under the curve was 0.996 
(95% confidence interval 0.986−1.000) (12).
DiscUssiOn
Here, we investigated four Japanese cases with APDS2 carrying 
a heterozygous mutation in PIK3R1. Elkaim et al. recently sum-
marized the clinical and immunological aspects of 36 genetically 
diagnosed APDS2 patients and revealed that recurrent upper 
respiratory tract infections (100%), pneumonitis (71%), and 
chronic lymphoproliferation (89%) were the most common 
clinical features (11). Malignant diseases were identified in 28% 
of patients, most of them were B-cell lymphomas. Laboratory 
findings showed that patients with APDS2 had decreased serum 
IgA and IgG levels (87%), increased IgM levels (58%), B-cell 
lymphopenia (88%), and an increased frequency of transitional 
B cells (93%) (11). All four patients developed recurrent upper or 
lower respiratory tract infections and showed decreased serum 
IgG, which required intravenous immunoglobulin replacement 
therapy. Elevated serum IgM was observed in two patients, and 
one patient developed malignant lymphoma. Therefore, the four 
Japanese patients in the current study were considered to be typi-
cal cases of APDS2.
The former diagnoses of the four patients in the current study 
were HIGM (P2 and P4), CVID (P1), and IgG subclass deficiency 
FigUre 4 |  (a) AKT phosphorylation (pAKT) expression in activated T cells, (B) pAKT expression CD19+ B cells stimulated with CD40L and IL-4. (a) The level of 
pAKT in T cells was assessed by flow cytometry in activated PI3Kδ syndrome 2 patient (P1) and healthy controls (representative result from two controls is shown). 
The total number of events analyzed was 2,000. Red bold line: no treatment and black dotted line: p110δ inhibitor treatment. (B) pAKT expression in CD19+ B cells 
from (P1) and healthy control following stimulation with CD40L and IL-4. Blue line: isotype control, black and red solid line: no treatment, and black and red dot line: 
CD40L and IL-4 treatment.
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(P3). Based on the phenotypic diversity and similarity in clinical 
and laboratory findings, considerable numbers of patients with 
APDS2, as well as patients with APDS1 (13), have been histori-
cally diagnosed as HIGM or CVID. From the first identification 
of APDS1 associated with hyperactive PI3K signaling, a definitive 
diagnosis of APDSs is performed by the identification of muta-
tions in PIK3CD or PIK3R1. In addition to these genetic tests, 
the detection of enhanced pAKT signaling in T-cell blasts by 
FigUre 5 | Enhanced AKT phosphorylation (pAKT) in activated PI3Kδ syndrome 2 (APDS2) patients was pronounced in a flow-cytometry assay of CD10+CD19+ 
B cells. (a,B) The enhancement of pAKT observed in CD19+ B cells was further investigated by separating them into CD10+CD19+ immature B cells and 
CD10−CD19+ mature B cells from P2 (representative histogram of three experiments) (a) and healthy controls (B). The number of events analyzed was >5,000.  
As an exception, CD10+CD19+ immature B cells analyzed in healthy control were 800 events. Red solid line: no treatment and black dotted line: p110δ inhibitor 
treatment. (c,D,e) A summary of difference in mean fluorescence intensity of CD19+ B cells (c), CD10−CD19+ mature B cells (D), and CD10+CD19+ immature 
B cells (e) from healthy controls or patients with APDS1 (three patients), APDS2 (P1, P2, and P4), or APDS-like (APDS-L) (three patients). *p < 0.05 and 
**p < 0.01.
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functional assays has been used to confirm hyperactive PI3K 
signaling. However, this assay method is not suitable for rapid 
diagnosis, because it requires the cultivation of T  cells. In the 
current study, we observed significantly higher levels of pAKT in 
CD19+ B cells, but not CD3+ T cells, CD16+CD56+ NK cells, or 
CD14+ monocytes isolated from fresh PBMCs from APDSs and 
APDS-L patients. The enhancement of pAKT in CD19+ B cells 
was pronounced in CD10+CD19+ immature B  cells. Moreover, 
when we focused on this CD10+CD19+ B-cell population, there 
was no overlap in the value of ΔMFI of pAKT between APDSs 
or APDS-L patients and the other populations, including healthy 
controls and patients with CVID or HIGM. We also made a 
similar observation using cryopreserved PBMCs from patients 
with APDSs or APDS-L. This finding allowed us to perform the 
rapid detection of hyperactive PI3K signaling without culturing 
patient cells. Although further studies are required to optimize 
and evaluate this flow-cytometry-based assay system, this assay 
system has a potential to enable a rapid diagnosis of APDSs and 
APDS-L
In this study, the enhanced ΔMFI of pAKT in CD19+ 
B  cells was a common finding among patients with APDSs or 
APDS-L. This observation was further enhanced if we focused 
TaBle 1 | Clinical features of patients with APDSs, APDS-L, or CVID.
clinical feature aPDs1 
(%)
aPDs2 
(%)
aPDs-l 
(%)
cViD 
(%)
Pneumonia 85 71 50 32–77
Lymphoproliferation 75 89 44 N.D.
Splenomegaly 58 43 N.D. 15–30
Enteropathy 25 24 N.D. 9
Granuloma 0 N.D. N.D. 8–9
Meningitis/encephalitis 1.9 N.D. N.D 3–4
Autoimmunity 42 17 N.D. 22–29
Malignancy 13 28 22 3–8
Neurodevelopmental delay 19 31 50 N.D.
IVIG therapy 77 89 19 80
Reference (20) (11) (5, 6) (20)
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on CD10+CD19+ immature B cells. These observations may reflect 
the importance of PI3K signaling in class-switch recombination 
in B cells (9, 14), and be related to abnormalities in the develop-
mental stages of B  cells, such as abnormalities of the germinal 
center structure (11, 15–17), increased circulating transitional 
B  cells, and decreased class switching B  cells in patients with 
APDSs (1–4). Curiously, the ΔMFI of pAKT was the highest in 
CD19+ B cells from APDS2 patients and was the lowest in CD19+ 
B cells from APDS-L patients. It is interesting to speculate pos-
sible molecular mechanism underlie this observation. The p85α 
is known to enhance enzymatic activity of PTEN (18). Although 
PTEN protein expression is normal in APDS2 patients (2), its 
enzymatic activity might be affected by functional impairment 
of p85α. Therefore, impairment of p85α may enhance pAKT by 
losing its inhibitory role of p110δ and its enhancing effect against 
PTEN enzymatic activity.
Relatively mild enhancement of pAKT in APDS-L patients 
might explain the clinical observation that only a part of patients 
with PHTS, caused by heterozygous mutations in PTEN, present 
with antibody deficiency (5). Indeed, the clinical penetrance of 
APDS-L is not high in patients with PHTS (19). There are consid-
erable overlaps in the clinical manifestations between APDS1 and 
APDS2 (Table 1) (1–4, 11, 20); however, there are also some dif-
ferences in these two disorders. Indeed, patients with APDS2 have 
a higher susceptibility to lymphoma than patients with APDS1 
(11, 20, 21) (Okano et al., under revision). The clinical penetrance 
of APDS1 is quite high, but not complete, possibly explaining the 
existence of asymptomatic carriers or cases with mild symptoms 
that only show recurrent respiratory infections and diagnosed as 
APDS1 by familial studies that identified a proband case (20). 
However, to date no asymptomatic carriers have been reported 
in patients with APDS2. Although we require large cohort studies 
to make strong conclusions, these clinical observations might be 
partially explained by the difference in elevated ΔMFI of pAKT. 
Further studies are necessary to understand the role of elevated 
ΔMFI of pAKT in CD19+ B cells on the immunological manifes-
tations among patients with APDSs and APDS-L. The selective 
effect of pAKT in B cells (transitional B cells in particular), which 
may provide a detailed pathological mechanism of APDSs and 
APDS-L, remains to be explained.
Recently, molecular targeting therapy using an mTOR inhibi-
tor was also effective for the treatment of lymphoproliferation 
in patients with APDSs (1, 3, 11). Therefore, the prompt and 
appropriate diagnosis of APDSs definitely benefits patients 
by providing a therapeutic choice of target therapy. The flow-
cytometry-based rapid assay of PI3K activity described here 
has the potential to provide a rapid diagnosis of APDSs and 
APDS-L.
cOnclUDing reMarKs
The flow-cytometry-based rapid assay of PI3K activity described 
here provides a rapid discrimination assay of identified mutations 
in PIK3CD, PIK3R1, and PTEN, and might also be a potential 
diagnostic tool for patients with APDSs or APDS-L.
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